OncoMatch/Clinical Trials/NCT03611595
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Is NCT03611595 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cabozantinib and 13-cis-retinoic acid for solid tumor.
Treatment: Cabozantinib · 13-cis-retinoic acid — This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Cannot have received: cabozantinib (cabozantinib)
Cannot have received: allogeneic stem cell transplantation
Cannot have received: total body irradiation
Lab requirements
Blood counts
absolute neutrophil count, hemoglobin, platelet count must have recovered to meet eligibility criteria
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrolment with the exception of hematologic parameters (absolute neutrophil count, hemoglobin, platelet count), which need to have recovered to meet eligibility criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rady Children's Hospital - San Diego · San Diego, California
- Children's Healthcare of Atlanta · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify